Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction
作者:Xiang Nan、Jing Zhang、Hui-Jing Li、Rui Wu、Sen-Biao Fang、Zhi-Zhou Zhang、Yan-Chao Wu
DOI:10.1016/j.ejmech.2020.112470
日期:2020.8
In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds
在我们不断努力开发新颖的c-Met抑制剂作为潜在的抗癌候选药物的过程中,设计了一系列新的N-磺酰lam啶衍生物,并通过Cu催化的多组分反应(MCR)合成了关键步骤,并对它们的体外生物学活性进行了评估。抗c-Met激酶和四种癌细胞系(A549,HT-29,MKN-45和MDA-MB-231)。大多数目标化合物在基于酶和基于细胞的测定中均显示出中等至显着的效力,并且对A549和HT-29癌细胞系具有选择性。SAR的初步研究表明,化合物26af(c-Met IC 50 与阳性的foretinib相比,它具有2.89 nM)的最有前途的化合物,后者具有显着的抗增殖活性,IC 50值为0.28至0.72μM。对26af的机理研究表明,抗癌活性与c-Met的阻断磷酸化密切相关,导致细胞周期停滞在G2 / M期,并以浓度依赖的方式导致A549细胞凋亡。有希望的化合物26af被进一步鉴定为c-Met激酶的相对选择性抑制剂,在BALB